ALZN
Alzamend Neuro, Inc.
Key Financials
Operating Income
$-8766841
↓ 95.0%
Total Assets
$2.1M
↓ 54.8%
Shareholders' Equity
$733211.00
↓ 66.7%
Cash & Equivalents
$710689.00
↓ 82.0%
Total Liabilities
$1.3M
↑ 112.1%
EPS (Diluted)
$-2.63
↑ 76.8%
Operating Cash Flow
$-8067813.00
↓ 22.8%
Net Income
$-8772382
↓ 94.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 9/29/2026 | View on SEC |
| 10-Q | 9/10/2026 | View on SEC |
| 4 | 8/31/2026 | View on SEC |
| 4/A | 8/31/2026 | View on SEC |
| 4/A | 8/31/2026 | View on SEC |
| PRE 14A | 8/28/2026 | View on SEC |
| S-1 | 8/21/2026 | View on SEC |
| 4/A | 8/20/2026 | View on SEC |
| 3/A | 8/20/2026 | View on SEC |
| 4 | 8/4/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ALZN |
| Company Name | Alzamend Neuro, Inc. |
| CIK | 1677077 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0430 |
| State of Incorporation | DE |
| Phone | 844-722-6333 |